Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL2821 Target Snapshot

Coagulation factor XII · SINGLE PROTEIN · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
1,792Compounds
126Assays
0Approved Drugs
1,823.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-14

Coagulation factor XII shows approved-linked disease relevance led by flatulence. 5 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt P00748. Start with flatulence, then reuse UniProt P00748 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with flatulence, then reuse UniProt P00748 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-14 1 linked drug
Open source guide
Disease program
flatulence

Coagulation factor XII shows approved-linked disease relevance led by flatulence. 5 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.

Start review with flatulence because it currently carries approved-linked support. Linked drugs include BISMUTH SUBGALLATE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Approved-linked Open Targets-ready proxy 1 linked drug
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Coagulation factor XII as ChEMBL target CHEMBL2821, mapped to UniProt P00748. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Coagulation factor XII
SINGLE PROTEIN · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL2821
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
P00748
Coagulation factor XII
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Coagulation factor XII is the right protein anchor across sources, using UniProt P00748 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why flatulence is currently framed as approved-linked support. It currently carries 1 linked drug in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameCoagulation factor XII
Target TypeSINGLE PROTEIN
OrganismHomo sapiens
UniProtP00748
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelCoagulation factor XII
UniProt AccessionP00748
Component TypeProtein
Sequence Length615 aa

Coagulation factor XII

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Coagulation factor XII, mapped to UniProt P00748. Sequence length is 615 aa.

Mapped IDP00748
Review nameCoagulation factor XII
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Approved-linked Open Targets-ready proxy

Coagulation factor XII shows approved-linked disease relevance led by flatulence. 5 more disease programs remain visible in the same review block.

Approved-linked Approved
flatulence
1 linked drug · 1 direct · 1 efficacy
Linked drugBISMUTH SUBGALLATE
Approved-linked Approved
hereditary angioedema
1 linked drug · 1 direct · 1 efficacy
Linked drugHUMAN C1-ESTERASE INHIBITOR
Late clinical Phase III
angioedema
1 linked drug · 1 direct · 1 efficacy
Linked drugHUMAN C1-ESTERASE INHIBITOR
Clinical signal Phase II
COVID-19
1 linked drug · 1 direct · 1 efficacy
Linked drugHUMAN C1-ESTERASE INHIBITOR
Clinical signal Phase I
chronic kidney disease
1 linked drug · 1 direct · 1 efficacy
Linked drugHUMAN C1-ESTERASE INHIBITOR
Clinical signal Phase I
kidney failure
1 linked drug · 1 direct · 1 efficacy
Linked drugHUMAN C1-ESTERASE INHIBITOR
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with flatulence because it currently carries approved-linked support. Linked drugs include BISMUTH SUBGALLATE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseaseflatulence
Strongest levelApproved-linked
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

2
Phase III
1
Phase II
Assay Mix

Activity Type Distribution

IC501,639.0
KI184.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL5758818 10.0 IC50 0.1 Preclinical
CHEMBL6054063 9.7 IC50 0.2 Preclinical
CHEMBL5805584 9.52 IC50 0.3 Preclinical
CHEMBL6043307 9.52 IC50 0.3 Preclinical
CHEMBL5923412 9.4 IC50 0.4 Preclinical
CHEMBL5777358 9.3 IC50 0.5 Preclinical
CHEMBL5864799 9.3 IC50 0.5 Preclinical
CHEMBL6046462 9.3 IC50 0.5 Preclinical
CHEMBL5895805 9.22 IC50 0.6 Preclinical
CHEMBL5850559 9.15 IC50 0.7 Preclinical
Distribution

pChEMBL Value Distribution

53
5.0
47
5.5
75
6.0
81
6.5
129
7.0
122
7.5
62
8.0
24
8.5
15
9.0
3
9.5
pChEMBL
Assay Landscape

Assay Landscape

126
Total Assays
699
Tested Compounds
3
Assay Types
Binding — 121 assays, 699 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 105 668 6.7
cell-free format 15 20 5.6
assay format 1 11 5.2
Functional — 3 assays, 0 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 3 0 —
ADME — 2 assays, 0 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 2 0 —

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine